|
1
|
Chen WQ, Zheng RS, Zeng HM, Zhang SW, Li
N, Zou XN and He J: Trend analysis and prediction of cancer
incidence in China. Zhonghua Yu Fang Yi Xue Za Zhi. 46:581–586.
2012.(In Chinese). PubMed/NCBI
|
|
2
|
Harstrick A, Bokemeyer C, Scharnofkse M,
Hapke G, Reile D and Schmoll HJ: Preclinical activity of a new
platinum analogue, lobaplatin, in cisplatin-sensitive and
-resistant human testicular, ovarian, and gastric carcinoma cell
lines. Cancer Chemother Pharmacol. 33:43–47. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gietema JA, Guchelaar HJ, de Vries EG,
Aulenbacher P, Sleijfer DT and Mulder NH: A Phase I study of
lobaplatin (D-19466) administered by 72 h continuous infusion.
Anticancer Drugs. 4:51–55. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lai SQ and Xu M:
Antineoplastic-lobaplatin. Shi Jie Lin Chuang Yao Wu.
26:3152005.(In Chinese).
|
|
5
|
Yang LQ and Qin SK: Progression of
lobaplatin as the third generation platinum drug. Lin Chuang Zhong
Liu Xue Za Zhi. 14:1134–1139. 2009.(In Chinese).
|
|
6
|
Mckeage MJ: Lobaplatin: a new antitumor
platinum drug. Expert Opin Investig Drugs. 10:119–128. 2001.
View Article : Google Scholar
|
|
7
|
Saris CP, van De Vaart PJ, Rietbroek RC
and Blommaert FA: In Vitro formation of DNA adducts by cisplatin,
lobaplatin and oxaliplatin in calf thymus DNA in solution and in
cultured human cells. Carcinogenesis. 17:2763–2769. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi J, Yuan ZF, Liu WN, et al: Study on
Lobaplatin Pharmacokinetic in Human Plasma and Tumor Tissue of
Malignant Patients. Zhongguo Yaoxue Zazhi. 24:1888–1891. 2007.(In
Chinese).
|
|
9
|
Welink J, Pechstein B and van der Vijgh
WJ: Determination of the two diastereoisomers of lobaplatin
(D-19466) in plasma ultrafiltrate of cancer patients with a normal
or an impaired kidney or liver function by high-performance liquid
chromatography with ultraviolet detection. J Chromatogr B Biomed
Appl. 675:107–111. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Deng QQ, Huang XE, Ye LH, Lu YY, Liang Y
and Xiang J: Phase II trial of Loubo® (Lobaplatin) and pemetrexed
for patients with metastatic breast cancer not responding to
anthracycline or taxanes. Asian Pac J Cancer Prev. 14:413–417.
2013. View Article : Google Scholar
|
|
11
|
Xie CY, Xu YP, Jin W and Lou LG: Antitumor
activity of lobaplatin alone or in combination with antitubulin
agents in non-small-cell lung cancer. Anticancer Drugs. 23:698–705.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Liu YG and Sun H: Clinical
observation of docetaxel plus lobaplatin in treating anthracyclines
resistant advanced breast cancer. Xian Dai Zhong Liu Xue Za Zhi.
3:473–474. 2011.(In Chinese).
|
|
13
|
Chouaid C, Atsou K, Hejblum G and
Vergnenegre A: Economics of treatments for non-small cell lung
cancer. Pharmacoeconomics. 27:113–125. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dancey J, Shepherd FA, Gralla RJ and Kim
YS: Quality of life assessment of second-line docetaxel versus best
supportive care in patients with non-small-cell lung cancer
previously treated with platinum-based chemotherapy: results of a
prospective, randomized phase III trial. Lung Cancer. 43:183–194.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Davies AM, Lara PN Jr, Mack PC and Gandara
DR: Docetaxel in non-small cell lung cancer: a review. Expert Opin
Pharmacother. 4:553–565. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nabholtz JM and Crown J: Phase III studies
of single-agent docetaxel in patients with metastatic breast cancer
who have progressed despite previous chemotherapy regimens:
preliminary results. Semin Oncol. 25:4–9. 1998.PubMed/NCBI
|
|
17
|
Fiebig HH, Henß H, Mross K, et al: Phase I
clinical trial of lobaplatin (D-19466) after intravenous bolus
injection. Onkologie. 17:142–148. 1994. View Article : Google Scholar
|
|
18
|
Manegold C, Drings P, Gatzemeier U, Pawel
Jv, Fiebig HH, Queißer W and Edler L: Lobaplatin (D-19466) in
Patients with Advanced Non-Small-Cell Lung Cancer: A Trial of the
Association for Medical Oncology (AIO) Phase II Study Group.
Onkologie. 19:248–251. 1996. View Article : Google Scholar
|
|
19
|
Degardin M, Armand JP, Chevallier B,
Cappelaere P, Lentz MA, David M and Roché H: A clinical screening
cooperative group phase II evaluation of lobaplatin (ASTA D-19466)
in advanced head and neck cancer. Invest New Drugs. 13:253–255.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kavanagh JJ, Edwards CL, Freedman RS, et
al: A trial of lobaplatin (D-19466) in platinum-resistant ovarian
cancer. Gynecol Oncol. 58:106–109. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huisman C, Smit EF, Giaccone G and Postmus
PE: Second-line chemotherapy in relapsing or refractory
non-small-cell lung cancer: a review. J Clin Oncol. 18:3722–3730.
2000.PubMed/NCBI
|
|
22
|
Lai CL, Tsai CM, Chiu CH, Wang GS, Su WJ,
Chen YM and Perng RP: Phase II randomized trial of tri-weekly
versus days 1 and 8 weekly docetaxel as a second-line treatment of
advanced non-small cell lung cancer. Jpn J Clin Oncol. 35:700–706.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kunitoh H, Watanabe K, Onoshi T, Furuse K,
Niitani H and Taguchi T: Phase II trial of docetaxel in previously
untreated advanced non-small-cell lung cancer: a Japanese
cooperativestudy. J Clin Oncol. 14:1649–1655. 1996.PubMed/NCBI
|
|
24
|
Nakamura Y, Kunitoh H, Kubota K, Sekine I,
Yamamoto N, Tamura T, et al: Retrospective analysis of safety and
efficacy of low-dose docetaxel 60 mg/m2 in advanced non-small cell
lung cancer patients previously treated with platinum-based
chemotherapy. Am J Clin Oncol. 26:459–464. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin Q, Gao XS, Qiao XY, et al: Phase I
trial of escalating-dose cisplatin with 5-fluorouracil and
concurrent radiotherapy in Chinese patients with esophageal cancer.
Acta Med Okayama. 62:37–44. 2008.PubMed/NCBI
|
|
26
|
Lin Q, Liu YE, Chang CL, et al: Phase I
trial of dose escalation of capecitabine combined with fixed
docetaxel in previously treated patients with non-small cell lung
cancer. Chinese-German Journal of Clinical Oncology. 11:6–10. 2012.
View Article : Google Scholar
|
|
27
|
Ardizzoni A, Tiseo M, Boni L, et al:
Pemetrexed versus pemetrexed and carboplatin as second-line
chemotherapy in advanced non-small-cell lung cancer: results of the
GOIRC 02-2006 randomized phase II study and pooled analysis with
the NVALT7 trial. J Clin Oncol. 30:4501–4507. PubMed/NCBI
|
|
28
|
Kim HJ, Yun J, Kim HJ, et al: Phase II
study of palliative S-1 in combination with cisplatin as
second-line chemotherapy for gemcitabine-refractory pancreatic
cancer patients. Oncol Lett. 3:1314–1318. PubMed/NCBI
|
|
29
|
DCTD, NCI, NIH and DHHS. Cancer Therapy
Evaluation Program, Common Toxicity Criteria for Adverse Events,
Version 3.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
Accessed October 30, 2014
|
|
30
|
Ratain MJ, Mick R, Schilsky RL and Siegler
M: Statistical and ethical issues in the design and conduct of
phase I and II clinical trials of new anticancer agents. J Natl
Cancer Inst. 85:1637–1643. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
32
|
Cho KH, Ahn SJ, Pyo HR, et al: A Phase II
study of synchronous three-dimensional conformal boost to the gross
tumor volume for patients with unresectable Stage III
non-small-cell lung cancer: results of Korean Radiation Oncology
Group 0301 study. Int J Radiat Oncol Biol Phys. 74:1397–1404. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ali I, Wani WA, Saleem K and Haque A:
Platinum compounds: a hope for future cancer chemotherapy.
Anticancer Agents in Med Chem. 13:296–306. 2013. View Article : Google Scholar
|
|
34
|
Wheate NJ, Walker S, Craig GE and Oun R:
The status of platinum anticancer drugs in the clinic and in
clinical trials. Dalton Trans. 39:8113–8127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cortes JE and Pazdur R: Docetaxel. J Clin
Oncol. 13:2643–2655. 1995.PubMed/NCBI
|
|
36
|
Yang LQ, Shi Y, Qin SK, et al: Clinical
study of Lobaplatin combined with Navelbine for advanced non-small
cell lung cancer. Lin Chuang Zhong Liu Xue Za Zhi. 12:890–894.
2006.(In Chinese).
|
|
37
|
He AB, Luo YX, Wang Q, Tong WX and Liu AH:
The efficacy of lobaplatin combined with docetaxel versus docetaxel
alone as the second-line treatment for advanced non-small cell lung
cancer. Lin Chuang Zhong Liu Xue Za Zhi. 10:923–926. 2012.(In
Chinese).
|
|
38
|
Weiss JM and Stinchcombe TE: Second-Line
Therapy for Advanced NSCLC. Oncologist. 18:947–953. 2013.
View Article : Google Scholar : PubMed/NCBI
|
